News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
Cholesterol transport protein emerges as possible target for Parkinson's treatment
Parkinson's disease (PD) is a neurodegenerative condition that causes the progressive loss of dopamine-producing neurons in a brain region called the substantia nigra. Its characteristic symptoms include tremors, slowed movements, rigid muscles and difficulties with balance.
Read at Medical Xpress →New dementia risk tool designed for the countries that need it most
An international team led by Northumbria University has developed and validated a simple five-factor risk score to identify older people at elevated risk of dementia in low- and middle-income countries (LMICs)—where around 60% of the world's dementia cases now occur.
Read at Medical Xpress →Cardiometabolic risk factors in midlife impact risk for dementia
BOSTON — Vascular pathology and changes in midlife play a major role in brain health later in life, suggesting that reducing cardiometabolic risk factors may lower risk for dementia and Alzheimer’s disease, according to a speaker. …
Free to read? Not known for this outlet.
Read at Healio → Archived copy (23 Oct 2026), Internet ArchiveADHD linked to higher risk for cognitive impairment, dementia
Among people aged 50 years and older, ADHD was associated with a more than four-fold higher risk for cognitive impairment, according to research published in JAMA Psychiatry. …
Free to read? Not known for this outlet.
Read at Healio → Archived copy (16 Oct 2026), Internet ArchiveHow the biggest Alzheimer's risk gene disrupts the process of insulating neurons
One of the main ways that the APOE4 gene variant, the biggest genetic risk factor for late-onset Alzheimer's disease, undermines brain circuit function is by disrupting the process of insulating neurons with a fatty sheath that optimizes their electrical transmission.
Read at Medical Xpress → Archived copy (16 Oct 2026), Internet ArchiveWhy hearing loss deserves earlier attention in dementia prevention
Dr. Brent Tipping, a geriatrician at Wits Donald Gordon Medical Center (WDGMC), says that hearing loss more than doubles the odds of dementia, with visual impairment (both near and far) also elevating the risk.
Genetic analysis reveals potential benefit of aspirin for reducing dementia risk
Low-dose aspirin was associated with a 70% lower risk of dementia among older people with a particular genetic profile, a new Monash University analysis has found, raising the possibility of a more personalized approach to dementia prevention.
Read at Medical Xpress →10 surprising ways diabetes and dementia are connected
Diabetes and dementia appear to be closely intertwined, with each condition potentially influencing the other. Problems with insulin and glucose can affect the brain’s energy supply, increase inflammation, and damage blood vessels linked to memory loss. …
- evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease
- Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment: Metformin in Alzheimer Dementia Prevention (MAP)
Follow new items in a feed reader: Atom feed.